13 February 2019 - Life-saving anti-cancer drugs, once hard to afford or find on the market by many patients in China, have become accessible for more under the country's reforms in recent years.

A State Council executive meeting chaired by Premier Li Keqiang decided Monday that China will further streamline the registration and approval of new anti-cancer drugs, announcing that experts will be invited to select new overseas drugs to meet urgent clinical needs, and import policies will be improved for a faster launch of the new drugs in China.

These are the most recent efforts to expand access to anti-cancer drugs made by China, which has seen more than 3.5 million new cases of cancer and more than 2 million cancer deaths every year, according to research data released in 2018.

Read ECNS article